Moderna stock
Price history
+794.91% over the period1 year: from $24.96 (November 13, 2025) to $223.37 (November 13, 2026), +794.91%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $223.37 |
| October 30, 2026 | $221.72 |
| September 30, 2026 | $192.57 |
| August 31, 2026 | $140.34 |
| July 31, 2026 | $54.82 |
| June 30, 2026 | $70.03 |
| May 29, 2026 | $47.19 |
| April 30, 2026 | $45.94 |
| March 31, 2026 | $50.80 |
| February 27, 2026 | $53.57 |
| January 30, 2026 | $44.07 |
| December 31, 2025 | $29.49 |
| November 28, 2025 | $25.98 |
| November 13, 2025 | $24.96 |
At a glance
The company
Biotechnology company developing messenger RNA medicines for respiratory, latent, enteric, public health and bacterial vaccines, plus oncology and rare disease therapeutics
Latest results
Quarter to September 30, 2026 · EPS $0.38 (estimate -$1.11)
TickerLandia's take on Moderna
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−20.45% from the 52-week high
Analysts · 23 analysts
Average target$158.47−29.05% vs. price
Buy 4 · Hold 16 · Sell 3 · Hold
TickerLandia Fingerprint: Moderna
Compared with similar companies: very strong momentum, very low profitability, and very high risk.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricevery high80
How much it costs relative to what it produces.
Metric Value Position in group Price/book 13.2 78 Price/sales 35.8 82 Profitabilityvery low11
How much it earns on revenue and capital.
Metric Value Position in group Gross margin −42.0% 2 Operating margin −80.8% 14 Net marginabove 100%: likely one-off items −110.5% 6 ROE −34.5% 13 ROA −10.0% 19 Earnings stabilitylow39
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 101.9% 34 Loss-making yearscounts in reverse: lower means more earnings stability 3 of 5 annual reports 43 Growthlow31
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) −53.44% 1 Revenue growth (year over year) +29.20% 61 Financial strengthlow26
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage −307.4 1 Debt/equitycounts in reverse: lower means more financial strength 0.62 19 Current ratio 3.62 57 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery strong100
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (6 months) +336.14% 100 Distance from 200-day average +131.68% 100 1-year return +794.91% 100 Relative strength (3 months) +261.95% 100 Riskvery high83
How much the price swings.
Metric Value Position in group Volatility (60 days) 94.7% 98 Beta (1 year) 2.36 89 Maximum drawdown (12 months) 34.2% 63
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Moderna is pricier than similar companies
Moderna's Price/book: 13.2, +83% against the median of a group of 11 similar companies (7.20).
Compared with 11 similar companies
| Metric | Moderna | Position in the group | Band |
|---|---|---|---|
| Operating margin | -80.8% | Low | |
| ROE | -34.5% | Low | |
| Debt/equity | 0.62 | Middle | |
| Price/book | 13.2 | Middle | |
| Net margin | -110.5% | Low |
Grey band: the middle half of the group; tick: the median; dot: Moderna. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$1.31B
Latest quarter · Q3 2026
Net income
$162M
Latest quarter · Q3 2026
Quarterly net margin
12.3%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $90.38B
- EPS
- -$7.04
- Volume
- 8.09M
- Daily trading
- €3.04B
- Dividend yield
- 0.00%
How Moderna is changing
All resultsRevenue grew 19.3% a year on average over the last 5 years
Operating margin fell from 48.9% to −158.1%
Revenue has fallen for 3 fiscal years in a row
Returns
Moderna returns
$1,000 invested in Moderna 5 years ago, on November 15, 2021, would be worth $950 today: −4.98% in total, −1.02% per year. This is the price return only: dividends are excluded.
| Period | Moderna | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +3.29% | −3.12% | $1,033 |
| 6 months | +343.02% | +1.58% | $4,430 |
| Year to date | +657.44% | +10.46% | $7,574 |
| 1 year | +794.91% | +12.23% | $8,949 |
| 3 years | +218.15% | +71.41% | $3,181 |
| 5 years | −4.98% | +61.48% | $950 |
Over the last 6 months it has done better than 100% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Moderna: technical analysis
Moderna is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 53.9% below its all-time closing high ($484.47, August 9, 2021).
- Trend
- Upward
- RSI (14 sessions)
- 50
- Between 30 and 70
- vs 200-session average
- +131.68%
Support and resistance
Price areas where Moderna has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$223.37
- Support$179.56−19.61%3 touches, last on October 27, 2026
- Support$59.51−73.36%3 touches, last on July 31, 2026
- Support$47.64−78.67%12 touches, last on August 3, 2026
Volatility and risk
Over the last year it has moved more than the S&P 500.
- Beta (1 year) vs S&P 500
- 2.36
- Volatility (60 sessions, annualised)
- 94.7%
- Largest fall in the last year
- −34.16%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Moderna: seasonality
Average monthly price change over 8 years
Over the last 8 years, the strongest month for Moderna has been November: +20.60% on average, positive in 5 years out of 7. The weakest has been December: −3.33% on average, positive in 3 years out of 7.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +11.23% | +3.23% | 5 of 8 |
| February | +1.61% | −9.00% | 3 of 8 |
| March | +1.86% | +2.73% | 4 of 8 |
| April | +9.65% | +2.09% | 5 of 8 |
| May | +5.78% | +3.09% | 5 of 8 |
| June | +3.86% | +1.09% | 4 of 8 |
| July | +6.61% | +3.77% | 5 of 8 |
| August | +11.66% | −8.17% | 3 of 8 |
| September | +2.99% | +1.69% | 5 of 8 |
| October | −0.93% | +0.26% | 4 of 8 |
| November | +20.60% | +2.29% | 5 of 7 |
| December | −3.33% | −3.44% | 3 of 7 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Moderna and its competitors
Moderna, Inc., a biotechnology company with 4,700 employees, develops messenger RNA medicines for markets in the United States, Europe and other regions. Its respiratory vaccines include COVID, RSV and seasonal influenza products under the Spikevax and mRESVIA names, while its portfolio also covers latent virus vaccines against cytomegalovirus and Epstein-Barr virus, public health vaccines against Zika, Nipah and Mpox, oncology therapeutics such as intismeran autogene, and rare disease treatments for propionic and methylmalonic acidemia and cystic fibrosis.
- Headquarters
- Cambridge, United States
- Employees
- 4,700
- Founded
- 2010
- Chief executive
- Stéphane Bancel
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| ModernaMRNA | $90.38B | -80.8% | — | +343.02% |
| Regeneron PharmaceuticalsREGN | $98.84B | 30.4% | 21.1 | +32.73% |
| argenxARGX | $60.37B | 31.9% | 33.3 | +19.60% |
| Vertex PharmaceuticalsVRTX | $136.56B | 37.8% | 34.7 | +18.88% |
| BeOne MedicinesONC | $47.58B | 17.8% | 53.4 | +31.59% |
| Royalty PharmaRPRX | $39.85B | 64.4% | 45.3 | +30.16% |
Same industry or related industries, similar size. Compare Moderna with its competitors · Full profile
